ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

Tarantino, P; Viale, G; Press, MF; Hu, X; Penault-Llorca, F; Bardia, A; Batistatou, A; Burstein, HJ; Carey, LA; Cortes, J; Denkert, C; Dieras, V; Jacot, W; Koutras, AK; Lebeau, A; Loibl, S; Modi, S; Mosele, MF; Provenzano, E; Pruneri, G; Reis-Filho, JS; Rojo, F; Salgado, R; Schmid, P; Schnitt, SJ; Tolaney, SM; Trapani, D; Vincent-Salomon, A; Wolff, AC; Pentheroudakis, G; Andre, F; Curigliano, G

Author(s): Tarantino, P; Viale, G; Press, MF; Hu, X; Penault-Llorca, F; Bardia, A; Batistatou, A; Burstein, HJ; Carey, LA; Cortes, J; Denkert, C; Dieras, V; Jacot, W; Koutras, AK; Lebeau, A; Loibl, S; Modi, S; Mosele, MF; Provenzano, E; Pruneri, G; Reis-Filho, JS; Rojo, F; Salgado, R; Schmid, P; Schnitt, SJ; Tolaney, SM; Trapani, D; Vincent-Salomon, A; Wolff, AC; Pentheroudakis, G; Andre, F; Curigliano, G;
Details: Publication Year 2023-08,Volume 34,Issue #8,Page 645-659
Journal Title: Annals of Oncology
Publication Type: Research article
Abstract: Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical questions, warranting the establishment of consensus to optimally treat patients with HER2-low breast tumors. Between 2022 and 2023, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process focused on HER2-low breast cancer. The consensus included a multidisciplinary panel of 32 leading experts in the management of breast cancer from nine different countries. The aim of the consensus was to develop statements on topics that are not covered in detail in the current ESMO Clinical Practice Guideline. The main topics identified for discussion were (i) biology of HER2-low breast cancer; (ii) pathologic diagnosis of HER2-low breast cancer; (iii) clinical management of HER2-low metastatic breast cancer; and (iv) clinical trial design for HER2-low breast cancer. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. A review of the relevant scientific literature was conducted in advance. Consensus statements were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This article presents the developed statements, including findings from the expert panel discussions, expert opinion, and a summary of evidence supporting each statement.
Keywords: Humans; Female; *Breast Neoplasms/diagnosis/drug therapy; Consensus; Medical Oncology; HER2-low; antibody-drug conjugates; breast cancer
Department(s): Laboratory Research
PubMed ID: 37269905
Publisher's Version: https://doi.org/10.1016/j.annonc.2023.05.008
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-08-20 06:18:00

Last Modified: 2024-08-20 06:56:39